A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.
Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...
An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following ...
The UCLA trial is currently enrolling patients. Clinical trial compares two targeted radiation therapies for recurrent prostate cancer. New AI tool, ProCUSNet, detects prostate cancer more accurately ...
Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and will never cause harm.
A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...
Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate cancer. The international study, published in The New England Journal of ...
Hosted on MSN
A True Game-Changer in Prostate Cancer: A Simple Genomic Test Can Tell Us Who Needs Hormone Therapy And Who Doesn’t
If you or a loved one are navigating the journey of prostate cancer, you know that every decision weighs heavily. You’ve likely faced surgery or initial treatments, only to encounter the fear that ...
SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits when apalutamide (Erleada) was added to salvage radiotherapy after radical ...
(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a ...
For men with a localized recurrence following prostate cancer radiotherapy, salvage treatment with either focal therapy or surgery may offer comparable long-term cancer control, but focal therapy ...
Add Yahoo as a preferred source to see more of our stories on Google. Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a clinical trial, called ANDROMEDA, to compare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results